3Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn' s disease : the ACCENT I randomised trial [J]. Lancet, 2002,359 : 1541-1549.
4Rutgeerts P,Sandborn WJ,Feagan BG,et al. Infliximab for induction and maintenance therapy for ulcerative colitis[J]. New Engl J Med,2005,353(23) :2462-2476.
5Arhur B,Miguel R. Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease[J]. Inflamm Bowel Dis, 2007,13 : 1424-1429.
7Working Group of the Japanese Society for Pediatric Gastroenterolo- gy, Hepatology and Nutrition, KonnoM, et al. Guidelines for the treatment of Crohn'sdisease in children [ J ]. Pediatr Int, 2006,48 ( 3 ) : 349 - 352.
8Miheller P, Lakatos P L,Horv6th G,et al. Efficacy and safety of in- fliximab induction therapy in Crohn' sDisease in CentraIEurope -aHungarian nationwide obser-vational study [ J ]. BMC Gastroen- tero1,2009 ,9 :66.
9Higashi D,Futami K, Egawa Y, et al. Infliximab treatment for anal fistula in patientswith Crohn' s disease [ J ]. Anticancer Res,2009, 29:927 - 933.
10Caspersen S, ElkjaerM, RiisL, et al. Inflixmi ab for inflammatory bowel disease in Denmark 1999 -2005:clinical outcome and follow- up evaluation ofmalignancy andmortality [ J ]. Clin Gastroenterol Hepato1,2008,6 : 1212 - 1217.
